Table 1.
Baseline Characteristics of Study Subjects
| Characteristics | Overall (n=128) |
CKD (n=64) |
Matched Controls (n=64) |
P-value |
|---|---|---|---|---|
| Age (years) | 67.5±9.8 | 68.6±10.1 | 66.3±9.4 | 0.192 |
| Male (%) | 68 (53.1) | 34 (53.1) | 34 (53.1) | 1.000 |
| BMI (kg/m2) | 28.0±6.6 | 29.8±7.5 | 26.3±5.0 | 0.004 |
| HDL | 50.5±15.0 | 48.7±16.2 | 52.0±13.9 | 0.298 |
| LDL | 100.4±32.1 | 94.6±28.3 | 105.3±34.4 | 0.113 |
| Triglyceride | 126.8±55.3 | 133.3±56.5 | 121.0±54.1 | 0.283 |
| Total cholesterol | 173.9±38.4 | 166.8±36.1 | 179.8±39.6 | 0.101 |
| Current smoker (%) | 13 (10.2) | 4 (6.3) | 9 (14.1) | 0.143 |
| Former smoker | 80 (54.7) | 33 (51.6) | 37 (57.8) | 0.594 |
| Diabetes Mellitus (%) | 33 (25.8) | 22 (34.4) | 11 (17.2) | 0.026 |
| Hyperlipidemia (%) | 84 (65.6) | 42 (65.6) | 42 (65.6) | 1.000 |
| Hypertension (%) | 98 (76.6) | 56 (87.5) | 42 (65.6) | 0.003 |
| No active cancer (%) | 45 (35.2) | 22 (34.4) | 23 (35.9) | 0.853 |
| Anti-hypertensive therapy (%) | 79 (61.7) | 52 (81.3) | 27 (42.2) | <0.001 |
| Statin Therapy (%) | 48 (37.5) | 27 (42.2) | 21 (32.8) | 0.273 |
| eGFR (mL/min/1.73m2) | 61.0±21.3 | 42.8±8.6 | 79.2±13.0 | <0.001 |
| Creatinine (mg/dL) | 1.21±0.41 | 1.52±0.35 | 0.89±0.17 | <0.001 |
| Framingham Risk Score * | 0.466 | |||
| Low (10-y risk <10%) | 51 (39.8) | 22 (34.4) | 29 (45.3) | |
| Medium (10-y risk 10%-20%) | 30 (23.4) | 14 (21.9) | 16 (25.0) | |
| High (10-y risk >20%) | 11 (8.6) | 7 (10.9) | 4 (6.3) |
BMI, body mass index; eGFR, estimated glomerfular filtration rate. All normally distributed Independent T test and Chi square test for frequencies.
*
available in 92 patients